References
- ACC/AHA2007ACC/AHA 2007. Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarctionJ Am Coll Cardiol50e117692738
- AntoniucciDRodriguezAHempelA2003A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarctionJ Am Coll Cardiol42187914662245
- AsterRH2005Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitorsChest12753S15706031
- AtwaterBDRoeMTMahaffeyKW2005Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes. A review and guide to patient selectionDrugs6531315669877
- BatchelorWBTollesonTRHuangY2002Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes. The COMPARE TrialCirculation106147012234950
- BertrandOFDe LarochellièreRRodés-CabauJ2006A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantationCirculation114263617145988
- BologneseLFalsiniGLiistroF2005Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trialJ Am Coll Cardiol4752216458130
- BraunwaldEAntmanEMBeasleyJW2002ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina)J Am Coll Cardiol40136612383588
- BurzottaFRomagnoliETraniC2003Intracoronary administration of abciximab acutely increases flow through culprit vessels of patients with acute coronary syndromes undergoing percutaneous coronary interventionCirculation108e13814610001
- CampoGValgimigliMGemmatiD2006Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY studyJ Am Coll Cardiol48217817161242
- DanziGBSesanaMCapuanoC2004Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular functionAm J Cardiol943515219505
- De LucaGSuryapranataHStoneGW2006Relationship between patient’s risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: A meta-regression analysis of randomized trialsJ Am Coll Cardiol4768516458158
- ErnstNSuryapranataHMiedemaK2004Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarctionJ Am Coll Cardiol44118715364318
- GowdaRMKhanIAVasavadaBC2004Therapeutics of Platelet Glycoprotein IIb/IIIa Receptor AntagonismAm J Therapeutics11302
- HongYJJeongMHKimW2004Effect of abciximab-coated stent on in-stent intimal hyperplasia in human coronary arteriesAm J Cardiol94105015476624
- KabbaniSSWatkinsMWAshikagaT2001Platelet reactivity characterized prospectively. A determinant of outcome 90 days after percutaneous coronary interventionCirculation10418111447083
- KabbaniSSWatkinsMWAshikagaT2003Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year laterAm J Cardiol9187612667577
- KastratiAMehilliJNeumannFJ2006Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. The ISAR-REACT 2 Randomized TrialJAMA295E1
- KastratiAMehilliJSchuhlenH2004A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrelN Engl J Med35023214724302
- KimWJeongMHKimKH2006The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro)-coated stent in acute myocardial infarctionJ Am Coll Cardiol4793316516074
- MagerDEMascelliMAKleimanNS2003Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplastyJ Pharma Exp Ther307969
- MarmurJDMitreCABarnathanE2006Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trialAm Heart J15287617070148
- MarmurJDPoludasuSAgarwalA2006Bolus-only platelet glyco-protein IIb-IIIa inhibition during percutaneous coronary interventionJ Invasive Cardiol1852117090813
- MatetzkySShenkmanBGuettaV2004Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarctionCirculation109317115184279
- MontalescotGAntoniucciDKastratiA2007Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients data with long-term follow-upEur Heart J2844317251257
- MontalescotGBarraganPWittenbergO2001Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarctionN Engl J Med344189511419426
- NeumannFJKastratiASchmittC2000Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarctionJ Am Coll Cardiol3591510732888
- RaveendranGTingHHBestPJ2007Eptifibatide vs. abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarctionMayo Clin Proc8219617290727
- SchneiderDJHerrmannHCLakkisN2002Enhanced early inhibition of platelet aggregation with an increased bolus of tirofibanAm J Cardiol90142112480064
- SchrorKWeberAA2003Comparative Pharmacology of GP IIb/IIIa AntagonistsJ Thromb Thrombolysis157114618072
- SchweigerMJChangeziHUNaglieri-PrescodD2003Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary interventionClin Ther2522512637122
- SilvaMAGandhiPJ2004Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?J Clin PharmTher29497
- StoneGWMcLaurinBTCoxDA2006Bivalirudin for patients with acute coronary syndromesN Engl J Med355220317124018
- StoneGWBertrandMEMosesJW2006Routine upstream initiation vs. deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. the ACUITY-TIMING trialJ Am Med Ass297591
- The CAPTURE Investigators1997Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE studyLancet34914299164316
- The EPIC Investigators1994Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplastyN Engl J Med3309568121459
- The EPILOG Investigators1997Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularizationN Engl J Med33616899182212
- The EPISTENT Investigators1998Randomised placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockadeLancet352879672272
- The GUSTO IV-ACS Investigators2001Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trialLancet357191511425411
- The PRISM PLUS Investigators1998Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarctionN Engl J Med33814889599103
- The PURSUIT Trial Investigators1998Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromesN Engl J Med3394369705684
- The RESTORE Investigators1997Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplastyCirculation9614459315530
- Task force for percutaneous coronary intervention of the european society of cardiology2005Guidelines for percutaneous coronary interventionEur Heart J2680415769784
- Task force for diagnosis and treatment of non ST-segment elavation acute coronary syndromes2007Guidelines for the diagnosis and treatment of non ST-segment elavation acute coronary syndromesEur Heart J28159817569677
- TopolEMoliternoDHerrmannH2001Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abcix imab, for the prevention of ischemic events with percutaneous coronary revascularizationN Engl J Med344188811419425
- TopolEJByzovaTVPlowEF1999Platelet GPIIb-IIIa blockersLancet3532279923894
- ValgimigliMPercocoGMalaguttiP2005Tirofiban and sirolimuseluting stent vs. abciximab and bare-metal stent for acute myocardial infarction: a randomized trialJAMA293210915870414
- WöhrleJGrebeOCNusserT2003Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplastyCirculation107184012682003